SBRT re-irradiation after prior SBRT in pancreatic cancer—outcomes and a focus on stomach and bowel toxicity
- 15 December 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Radiation Oncology
- Vol. 9 (3-4), 235-241
- https://doi.org/10.1007/s13566-020-00443-x
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Reirradiation with stereotactic body radiation therapy after prior conventional fractionation radiation for locally recurrent pancreatic adenocarcinomaAdvances in Radiation Oncology, 2017
- Recent Advances and Prospects for Multimodality Therapy in Pancreatic CancerSeminars in Radiation Oncology, 2016
- Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without ErlotinibJAMA, 2016
- Stereotactic Body Radiotherapy (SBRT) Reirradiation for Recurrent Pancreas CancerJournal of Cancer, 2016
- Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolidative ChemoradiationEndocrine, 2015
- Phase 2 multi‐institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinomaCancer, 2014
- Re-irradiation with stereotactic body radiation therapy as a novel treatment option for isolated local recurrence of pancreatic cancer after multimodality therapy: experience from two institutions2013
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus GemcitabineThe New England Journal of Medicine, 2013
- Stereotactic Body Radiation Therapy for Locally Advanced and Borderline Resectable Pancreatic Cancer Is Effective and Well ToleratedEndocrine, 2013
- Surgery for Recurrent Pancreatic Ductal AdenocarcinomaAnnals of Surgery, 2007